The retinoblastoma tumor suppressor gene, Rb, was the first tumor suppressor identified and plays a fundamental role in regulation of progression through the cell cycle. This review details facets of RB protein function in cell cycle control and focuses on specific questions that remain intensive areas of investigation.
HuntleyR, HealyS, FreemanD, LavenderP, de JagerS, GreenwoodJ, MakkerJ, WalkerE, JackmanM, XieQ, BannisterAJ, KouzaridesT, GutierrezC, DoonanJH, MurrayJA. The maize retinoblastoma protein homologue ZmRb-1 is regulated during leaf development and displays conserved interactions with G1/S regulators and plant cyclin D (CycD) proteins. Plant Mol Biol37: 155–169, 1998.
TanakaEM, GannAA, GatesPB, BrockesJP. Newt myotubes reenter the cell cycle by phosphorylation of the retinoblastoma protein. J Cell Biol136: 155–165, 1997.
4.
BenevolenskayaEV, MurrayHL, BrantonP, YoungRA, KaelinWGJr.. 2005. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell18: 623–635, 2005.
5.
KorethJ, van den HeuvelS. Cell-cycle control in Caenorhabditis elegans: how the worm moves from G1 to S. Oncogene24: 2756–2764, 2005.
6.
KnudsonAGJr.. Mutation and cancer, statistical study of retinoblastoma. Proc Natl Acad Sci U S A68: 820–823, 1971.
7.
CaveneeWK, DryjaTP, PhillipsRA, BenedictWF, GodboutR, GallieBL, MurphreeAL, StrongLC, WhiteRL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature305: 779–784, 1983.
8.
GodboutR, DryjaTP, SquireJ, GallieBL, PhillipsRA. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature304: 451–453, 1983.
9.
LeeWH, BooksteinR, HongF, YoungLJ, ShewJY, LeeEY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science235: 1394–1399, 1987.
10.
FungYK, MurphreeAL, T'angA, QianJ, HinrichsSH, BenedictWF. Structural evidence for the authenticity of the human retinoblastoma gene. Science236: 1657–1661, 1987.
11.
FriendSH, BernardsR, RogeljS, WeinbergRA, RapaportJM, AlbertDM, DryjaTP. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature323: 643–646, 1986.
12.
SherrCJ. Cell cycle control and cancer. Harvey Lect96: 73–92, 2000.
13.
NevinsJr.. The Rb/E2F pathway and cancer. Hum Mol Genet10: 699–703, 2001.
14.
BartekJ, BartkovaJ, LukasJ. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res237: 1–6, 1997.
15.
PalmeroI, PetersG. Perturbation of cell cycle regulators in human cancer. Cancer Surv27: 351–367, 1996.
16.
CobrinikD. Pocket proteins and cell cycle control. Oncogene24: 2796–2809, 2005.
17.
WhyteP, BuchkovichKJ, HorowitzJM, FriendSH, RaybuckM, WeinbergRA, HarlowE. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature334: 124–129, 1988.
18.
MungerK, WemessBA, DysonN, PhelpsWC, HarlowE, HowleyPM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J8: 4099–4105, 1989.
19.
DysonN, HowleyPM, MungerK, HarlowE. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science243: 934–937, 1989.
20.
DysonN, BernardsR, FriendSH, GoodingLR, HassellJA, MajorEO, PipasJM, VandykeT, HarlowT. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol64: 1353–1356, 1990.
21.
MorrisEJ, DysonNJ. Retinoblastoma protein partners. Adv Cancer Res82: 1–54, 2001.
22.
WangJY, KnudsenES, WelchPJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res64: 25–85, 1994.
23.
KaelinWGJr., KrekW, SellersWR, DeCaprioJA, AjchenbaumF, FuchsCS, ChittendenT, LiY, FarnhamPJ, BlanarMA, LivingstonDM, FlemingtonEK. 1992. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell70: 351–364, 1992.
24.
ChellappanSP, HiebenS, MudryjM, HorowitzJM, NevinsJr.. The E2F transcription factor is a cellular target for the RB protein. Cell65: 1053–1061, 1991.
25.
IshidaS, HuangE, ZuzanH, SpangR, LeoneG, WestM, NevinsJr.. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol21: 4684–4699, 2001.
26.
ZhuW, GiangrandePH, NevinsJr.. E2Fs link the control of G1/S and G2/M transcription. Embo J23: 4615–4626, 2004.
27.
RenB, CamH, TakahashiY, VolkertT, TerragniJ, YoungRA, DynlachtBD. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev16: 245–256, 2002.
28.
CamH, DynlachtBD. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell3: 311–316, 2003.
29.
BiaisA, DynlachtBD. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev14: 527–532, 2004.
30.
WeintraubSJ, ChowKN, LuoRX, ZhangSH, HeS, DeanDC. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature375: 812–815, 1995.
31.
LuoRX, PostigoAA, DeanDC. Rb interacts with histone deacetylase to repress transcription. Cell92: 463–473, 1998.
HeS, CookBL, DevermanBE, WeiheU, ZhangF, PrachandV, ZhengJ, WeintraubSJ. E2F is required to prevent inappropriate S-phase entry of mammalian cells. Mol Cell Biol20: 363–371, 2000.
34.
RowlandBD, DenissovSG, DoumaS, StunnenbergHG, BernardsR, PeeperDS. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell2: 55–65, 2002.
35.
ZhangHS, PostigoAA, DeanDC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell97: 53–61, 1999.
36.
MarkeyMP, AngusSP, StrobeckMW, WilliamsSL, GunawardenaRW, AronowBJ, KnudsenES. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res62: 6587–6597, 2002.
37.
VemellR, HeiinK, MullerH. Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem278: 46124–46137, 2003.
38.
BuchkovichK, DuffyLA, HarlowE. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell58: 1097–1105, 1989.
39.
KnudsenES, WangJY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem271: 8313–8320, 1996.
40.
KnudsenES, WangJY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol17: 5771–5783, 1997.
41.
LudlowJW, DeCaprioJA, HuangCM, LeeWH, PauchaE, LivingstonDM. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell56: 57–65, 1989.
42.
HarbourJW, LuoRX, Dei SantiA, PostigoAA, DeanDC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell98: 859–869, 1999.
43.
RubinSM, GallAL, ZhengN, PavletichNP. Structure of the Rb C-terminal domain bound to E2F1–DP1: a mechanism for phosphorylation-induced E2F release. Cell123: 1093–1106, 2005.
44.
MittnachtS. Control of pRB phosphorylation. Curr Opin Genet Dev8: 21–27, 1998.
45.
SherrCJ, RobertsJM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev13: 1501–1512, 1999.
46.
ReedSI. Control of the G1/S transition. Cancer Surv29: 7–23, 1997.
47.
DiehlJA. Cycling to cancer with cyclin D1. Cancer Biol Ther1: 226–231, 2002.
48.
DeshpandeA, SicinskiP, HindsPW. Cyclins and cdks in development and cancer: a perspective. Oncogene24: 2909–2915, 2005.
49.
RubinE, TamrakarS, LudlowJW. Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Front Biosci3:D1209–D1219, 1998.
50.
TamrakarS, RubinE, LudlowJW. Role of pRB dephosphorylation in cell cycle regulation. Front Biosci5:D121–D137, 2000.
51.
TamrakarS, MittnachtS, LudlowJW. Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity. Oncogene18: 7803–7809, 1999.
52.
LudlowJW, GlendeningCL, LivingstonDM, DeCaprioJA. Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol13: 367–372, 1993.
53.
NelsonDA, LudlowJW. Characterization of the mitotic phase pRb-directed protein phosphatase activity. Oncogene14: 2407–2415, 1997.
54.
KayeFJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene21: 6908–6914, 2002.
55.
OttersonGA, KratzkeRA, CoxonA, KimYW, KayeFJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene9: 3375–3378, 1994.
56.
LukasJ, HerzingerT, HansenK, MoroniMC, ResnitzkyD, HelinK, ReedSI, BartekJ. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev11: 1479–1492, 1997.
57.
KnudsenES, BuckmasterC, ChenTT, FeramiscoJR, WangJY. Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev12: 2278–2292, 1998.
58.
LukasJ, SorensenCS, LukasC, Santoni-RugiuE, BartekJ. p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene18: 3930–3935, 1999.
59.
LengX, Connell-CrowleyL, GoodrichD, HarperJW. S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol7: 709–712, 1997.
60.
ChewYP, EllisM, WilkieS, MittnachtS. pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F. Oncogene17: 2177–2186, 1998.
61.
AngusSP, FribourgAF, MarkeyMP, WilliamsSL, HornHF, DeGregoriJ, KowalikTF, FukasawaK, KnudsenES. Active RB elicits late G1/S inhibition. Exp Cell Res276: 201–213, 2002.
62.
HarringtonEA, BruceJL, HarlowE, DysonN. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci U S A95: 11945–11950, 1998.
63.
NaderiS, WangJY, ChenTT, GutzkowKB, BlomhoffHK. cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cipl, and PCNA. Mol Biol Cell16: 1527–1542, 2005.
64.
SaudanP, VlachJ, BeardP. Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. Embo J19: 4351–4361, 2000.
65.
KennedyBK, BarbieDA, ClassonM, DysonN, HarlowE. Nuclear organization of DNA replication in primary mammalian cells. Genes Dev14: 2855–2868, 2000.
66.
DimitrovaDS, BerezneyR. The spatio-temporal organization of DNA replication sites is identical in primary, immortalized and transformed mammalian cells. J Cell Sci115: 4037–4051, 2002.
67.
AvniD, YangH, MartelliF, HofmannF, ElShamyWM, GanesanS, ScullyR, LivingstonDM. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell12: 735–746, 2003.
68.
SternerJM, Dew-KnightS, MusahlC, KombluthS, HorowitzJM. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol Cell Biol18: 2748–2757, 1998.
69.
AngusSP, MayhewCN, SolomonDA, BradenWA, MarkeyMP, OkunoY, CardosoMC, GilbertDM, KnudsenES. RB reversibly inhibits DNA replication via two temporally distinct mechanisms. Mol Cell Biol24: 5404–5420, 2004.
70.
Sever-ChroneosZ, AngusSP, FribourgAF, WanH, TodorovI, KnudsenKE, KnudsenES. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Mol Cell Biol21: 4032–4045, 2001.
BuchkovichK, DysonN, WhyteP, HarlowE. Cellular proteins that are targets for transformation by DNA tumour viruses. Ciba Found Symp150: 262–271; discussion 271–268, 1990.
75.
EcknerR, LudlowJW, LillNL, OldreadE, AranyZ, ModjtahediN, DeCaprioJA, LivingstonDM, MorganJA. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol16: 3454–3464, 1996.
76.
AliSH, DeCaprioJA. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin Cancer Biol11: 15–23, 2001.
77.
MaiA, ChattopadhyayD, GhoshMK, PeonRY, HunterT, HarterML. p21 and retinoblastoma protein control the absence of DNA replication in terminally differentiated muscle cells. J Cell Biol149: 281–292, 2000.
78.
HerreraRE, SahVP, WilliamsBO, MakelaTP, WeinbergRA, JacksT. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol16: 2402–2407, 1996.
79.
HerreraRE, ChenF, WeinbergRA. Increased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts. Proc Natl Acad Sci U S A93: 11510–11515, 1996.
80.
HerreraRE, MakelaTP, WeinbergRA. TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. Mol Biol Cell7: 1335–1342, 1996.
81.
MayhewCN, PerkinLM, ZhangX, SageJ, JacksT, KnudsenES. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene23: 4107–4120, 2004.
82.
SageJ, MillerAL, Perez-ManceraPA, WysockiJM, JacksT. Acute mutation of retinoblastoma gene function is sufficient for cell cycle reentry. Nature424: 223–228, 2003.
83.
NaritaM, NunezS, HeardE, LinAW, HearnSA, SpectorDL, HannonGJ, LoweSW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell113: 703–716, 2003.
BoscoEE, KnudsenES. Differential role of RB in response to UV and IR damage. Nucleic Acids Res33: 1581–1592, 2005.
89.
GrosselMJ, HindsPW. From cell cycle to differentiation: an expanding role for cdk6. Cell Cycle5: 266–270, 2006.
90.
NaritaM, LoweSW. Senescence comes of age. Nat Med11: 920–922, 2005.
91.
SerranoM, BlascoMA. Putting the stress on senescence. Curr Opin Cell Biol13: 748–753, 2001.
92.
KiyonoT, FosterSA, KoopJI, McDougallJK, GallowayDA, KlingelhutzAJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature396: 84–88, 1998.
93.
SerranoM, LinAW, McCurrachME, BeachD, LoweSW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell88: 593–602, 1997.
94.
NovitchBG, SpicerDB, KimPS, CheungWL, LassarAB. pRb is required for MEF2-dependent gene expression as well as cell-cycle arrest during skeletal muscle differentiation. Curr Biol9: 449–459, 1999.
95.
ChenTT, WangJY. Establishment of irreversible growth arrest in myogenic differentiation requires the RB LXCXE-binding function. Mol Cell Biol20: 5571–5580, 2000.
96.
TiainenM, SpitkovskyD, Jansen-DurrP, SacchiA, CrescenziM. Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms. Mol Cell Biol16: 5302–5312, 1996.
97.
ThomasDM, CartySA, PiscopoDM, LeeJS, WangWF, ForresterWC, HindsPW. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell8: 303–316, 2001.
98.
ScheijenB, BronkM, van der MeerT, BernardsR. Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation. Mol Cell Biol23: 3656–3668, 2003.
99.
HansenJB, JorgensenC, PetersenRK, HallenborgP, De MatteisR, BoyeHA, PetrovicN, EnerbackS, NedergaardJ, CintiS, te RieleH, KristiansenL. Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation. Proc Natl Acad Sci U S A101: 4112–4117, 2004.
100.
KouzaridesT. Transcriptional regulation by the retinoblastoma protein. Trends Cell Biol3: 211–213, 1993.
101.
GuW, SchneiderJW, CondorelliG, KaushalS, MahdaviV, Nadal-GinardB. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell72: 309–324, 1993.
102.
VelcichA, ZiffE. Adenovirus E1a ras cooperation activity is separate from its positive and negative transcription regulatory functions. Mol Cell Biol8: 2177–2183, 1988.
103.
KendallSD, LinardicCM, AdamSJ, CounterCM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res65: 9824–9828, 2005.
104.
BoehmJS, HessionMT, BulmerSE, HahnWC. Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol25: 6464–6474, 2005.
105.
WilliamsJP, StewartT, LiB, MulloyR, DimovaD, ClassonM. The retinoblastoma protein is required for Ras-induced oncogenic transformation. Mol Cell Biol26: 1170–1182, 2006.
106.
DeGregoriJ. Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis. Mol Cell Biol26: 1165–1169, 2006.
107.
RuizS, SantosM, LaraMF, SegrellesC, BallestinC, ParamioJM. Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res65: 9678–9686, 2005.
108.
HarveyM, VogelH, LeeEY, BradleyA, DonehowerLA. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res55: 1146–1151, 1995.
109.
NikitinAY, Juarez-PerezMI, LiS, HuangL, LeeWH. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb mice. Proc Natl Acad Sci U S A96: 3916–3921, 1999.
110.
JacksT, FazeliA, SchmittEM, BransonRT, GoodellMA, WeinbergRA. Effects of an Rb mutation in the mouse. Nature359: 295–300, 1992.
111.
LeeEY, ChangCY, HuN, WangYC, LaiCC, HerrupK, LeeWH, BradleyA. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature359: 288–294, 1992.
112.
ClarkeAR, MaandagER, van RoonM, van der LugtNM, van der ValkM, HooperML, BernsA, te RieleH. Requirement for a functional Rb-1 gene in murine development. Nature359: 328–330, 1992.
113.
VooijsM, van der ValkM, te RieleH, BernsA. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. Oncogene17: 1–12, 1998.
114.
MarinoS, VooijsM, van Der GuldenH, JonkersJ, BernsA. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev14: 994–1004, 2000.
115.
MacPhersonD, SageJ, CrowleyD, TrumppA, BransonRT, JacksT. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol Cell Biol23: 1044–1053, 2003.
116.
Flesken-NikitinA, ChoiKC, EngJP, ShmidtEN, NikitinAY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res63: 3459–3463, 2003.
117.
MeuwissenR, LinnSC, LinnoilaRI, ZevenhovenJ, MooiWJ, BernsA. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell4: 181–189, 2003.
118.
Wikenheiser-BrokampKA. Rb family proteins differentially regulate distinct cell lineages during epithelial development. Development131: 4299–4310, 2004.
119.
MayhewCN, BoscoEE, FoxSR, OkayaT, TaraporeP, Schwem-bergerSJ, BabcockGF, LentschAB, FukasawaK, KnudsenES. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res65: 4568–4577, 2005.
120.
RuizS, SantosM, SegrellesC, LeisH, JorcanoJL, BernsA, ParamioJM, VooijsM. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development131: 2737–2748, 2004.
121.
BalsitisS, DickF, LeeD, FarrellL, HydeRK, GriepAE, DysonN, LambertPF. Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J Virol79: 11392–11402, 2005.
122.
LeeMH, WilliamsBO, MulliganG, MukaiS, BransonRT, DysonN, HarlowE, JacksT. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev10: 1621–1632, 1996.
123.
Robanus-MaandagE, DekkerM, van der ValkM, CarrozzaML, JeannyJC, DannenbergJH, BernsA, te RieleH. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev12: 1599–1609, 1998.
124.
ChenD, Livne-barI, VanderluitJL, SlackRS, AgochiyaM, BremnerR. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell5: 539–551, 2004.
125.
DannenbergJH, SchuijffL, DekkerM, van der ValkM, te RieleH. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev18: 2952–2962, 2004.
126.
WhiteAE, LivanosEM, TlstyTD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev8: 666–677, 1994.
127.
LohezOD, ReynaudC, BorelF, AndreassenPR, MargolisRL. Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. J Cell Biol161: 67–77, 2003.
128.
ZhengL, LeeWH. Retinoblastoma tumor suppressor and genome stability. Adv Cancer Res85: 13–50, 2002.
129.
ZhengL, Flesken-NikitinA, ChenPL, LeeWH. Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res62: 2498–2502, 2002.
130.
KhanSH, WahlGM. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res58: 396–401, 1998.
131.
Di LeonardoA, KhanSH, LinkeSP, GrecoV, SeiditaG, WahlGM. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res57: 1013–1019, 1997.
132.
GonzaloS, Garcia-CaoM, FragaMF, SchottaG, PetersAH, CotterSE, EguiaR, DeanDC, EstellerM, JenuweinT, BlascoMA. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol7: 420–428, 2005.
133.
LanZ, Sever-ChroneosZ, StrobeckMW, ParkCH, BaskaranR, EdelmannW, LeoneG, KnudsenES. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem277: 8372–8381, 2002.
134.
AlmasanA, YinY, KellyRE, LeeEY, BradleyA, LiW, BertinoJR, WahlGM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Nad Acad Sci U S A92: 5436–5440, 1995.
135.
ChauBN, WangJY. Coordinated regulation of life and death by RB. Nat Rev Cancer3: 130–138, 2003.
136.
HarbourJW, DeanDC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol2:E65–E67, 2000.
137.
NahleZ, PolakoffJ, DavuluriRV, McCurrachME, JacobsonMD, NaritaM, ZhangMQ, LazebnikY, Bar-SagiD, LoweSW. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol4: 859–864, 2002.
JohnsonDG. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog27: 151–157, 2000.
140.
RogoffHA, KowalikTF. Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell Cycle3: 845–846, 2004.
141.
PowersJT, HongS, MayhewCN, RogersPM, KnudsenES, JohnsonDG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res2: 203–214, 2004.
142.
DeGregoriJ. E2F and cell survival: context really is key. Dev Cell9: 442–444, 2005.
143.
DimovaDK, DysonNJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene24: 2810–2826, 2005.
144.
KaelinWGJr.. E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biol Ther2:S48–S54, 2003.
145.
RogoffHA, PickeringMT, FrameFM, DebatisME, SanchezY, JonesS, KowalikTF. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol24: 2968–2977, 2004.
146.
RogoffHA, PickeringMT, DebatisME, JonesS, KowalikTF. E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol22: 5308–5318, 2002.
147.
KnudsenKE, ArdenKC, CaveneeWK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem273: 20213–20222, 1998.
148.
PrallOW, SarcevicB, MusgroveEA, WattsCK, SutherlandRL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem272: 10882–10894, 1997.
149.
FryDW, HarveyPJ, KellerPR, ElliottWL, MeadeM, TrachetE, AlbassamM, ZhengX, LeopoldWR, PryerNK, ToogoodPL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther3: 1427–1438, 2004.
150.
SmithBJ, O'brienJM. The genetics of retinoblastoma and current diagnostic testing. J Pediatr Ophthalmol Strabismus33: 120–123, 1996.
151.
GoddardAD, PhillipsRA, GregerV, PassargeE, HoppingW, ZhuXP, GallieBL, HorsthemkeB. Use of the RBI cDNA as a diagnostic probe in retinoblastoma families. Clin Genet37: 117–126, 1990.
152.
NicholsKE, HouseknechtMD, GodmilowL, BuninG, ShieldsC, MeadowsA, GangulyA. Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RBI gene. Hum Mutat25: 566–574, 2005.
153.
HietanenS, LainS, KrauszE, BlattnerC, LaneDP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A97: 8501–8506, 2000.
154.
VassilevLT, VuBT, GravesB, CarvajalD, PodlaskiF, FilipovicZ, KongN, KammlottU, LukacsC, KleinC, FotouhiN, LiuEA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science303: 844–348, 2004.
155.
Gomez-ManzanoC, YungWK, AlemanyR, FueyoJ. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology63: 418–426, 2004.
156.
FueyoJ, Gomez-ManzanoC, AlemanyR, LeePS, McDonnellTJ, MitliangaP, ShiYX, LevinVA, YungWK, KyritsisAP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene19: 2–12, 2000.
